Health Economics

Cost-effectiveness of BPaL/BPaLM regimen for MDR/RR-TB compared with the shorter oral bedaquiline-containing regimen under the National TB Elimination Programme (NTEP).

Economic evaluation of shortened, bedaquiline-containing treatment regimens for MDR/RR-TB evaluated in STREAM Stage 2

Cost-effectiveness of implementing the Cy-Tb test to screen latent tuberculosis infection in India.

The Cost-Effectiveness of the BEAT-TB Regimen for Pre-Extensively Drug-Resistant TB in India

Catastrophic costs due to tuberculosis in South India: comparison between active and passive case finding

Key Areas of Research

To evaluate the role of TB control programme in reducing out of pocket expenditure due to TB.

Studies to identify factors contributing to catastrophic expenditure and developing strategies to reduce it.

To undertake HTA analysis and provide scientific evidence to implement cost-effective and sustainable new health technologies in the country

Towards the aim to achieve Evidence based clinical practice guidelines (CPGs) development we will synthesis the evidence and provide recommendations that assist clinicians and policymakers in making informed healthcare decisions.

Modeling the macroeconomic benefits of TB elimination strategies

List of ongoing projects

Cost comparison of UniAMP sputum swab and Tongue swab UniAMP MTB for Tuberculosis in India

Cost comparison of MERINAT diagnostic platforms for tuberculosis in India

Cost effectiveness of Nicotine replacement therapy, Bupropion and Varenicline vs Placebo for smoking cessation in people who smoke tobacco

Costing of Health Services in India (CHSI) 2.0: Collection of Hospital-wise and Speciality-wise Claims Data from PM-JAY Empanelled Private Hospitals in Chennai and Thiruvallur Districts, Tamil Nadu CHSI 2.0 (PGIMER)

Cost-effectiveness of plasma exchange (PLEX) treatment for rodenticide poisoning cases (Yellow Phosphorous) with severe liver injury in Tamil Nadu

Lifestyle Interventions to Prevent or Delay the Onset of Polycystic Ovary Syndrome among Adolescent Girls: A Systematic Review and Meta-analysis

Effects of Bariatric Surgery on Reproductive, Metabolic, and Gynaecological Outcomes in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

Advanced data analysis software (TreeAge), modelling platforms, secure data infrastructure and HTA focused research facilities.

Malaisamy Muniyandi, Karikalan Nagarajan, Karthick Chelvanayagam, Kavitha Rajsekar, Kirti Tyagi, Chandrasekaran Padmapriyadarsini. Cost-effectiveness of BPaL/BPaLM as compared to mixed standard of care Bedaquiline containing regimen for MDR/RR-TB. Indian J Med Res 2025; 162: 581-591.

Malaisamy Muniyandi, Balaji Ramraj, Sathishkumar Vadamalai, Sahil Abdul Salam, Bella Devaleenal Daniel, Jyoti Jaju, Chandrasekaran Padmapriyadarsini. Comparing Cost-Effectiveness of Short Course Regimens for Drug-Resistant Tuberculosis Treatment in India. International Journal of Technology Assessment in Health Care 2025; 41(1), e48, 1–12.

Malaisamy Muniyandi, Kavi M, N Karikalan. Self-reported prevalence of tuberculosis: unveiling spatial representation in the districts of Tamil Nadu. Int Health. 2025 May 1;17(3):366-376.

Malaisamy Muniyandi, Karikalan Nagarajan, Kavi Mathiyazhagan, Kirti Tyagi, Kavitha Rajsekar, Chandrasekaran Padmapriyadarsini. Evaluating the cost-effectiveness of Cy-Tb for LTBI in India:a comprehensive economic modelling analysis. International Health 2025; 17(3), 259–269.

Malaisamy Muniyandi, Karikalan N, Kavi M, Prathiksha G, Kannan T, Rajendran K. The Predicted Potential Impact of COVID-19 Pandemic on Tuberculosis Epidemic in Tamil Nadu, South India. Trop Med Infect Dis 2024; 9, 12.

Malaisamy Muniyandi, Ramesh PM, Wells WA, Alavadi U, Sahu S, Padmapriyadarsini C. The Cost-Effectiveness of the BEAT-TB Regimen for Pre-Extensively Drug-Resistant TB. Tropical Medicine and Infectious Disease 2023; 8(8): 411.

Laura R, Jason JM, Ewan MT, Malaisamy Muniyandi, Jasper N, Mamo G, Valentina V, Priyanka B, Rajdeep D, Adamu BK, Daniel MK, Narendran G, R Solanki, Anuj KB, Elena T, Bruce K, Sarah M, Andrew N, Gay B, ID Rusen, SB Squire, E Worrall. Within-trial economic evaluation of shortened, bedaquiline-containing treatment regimens for MDR/RR-TB evaluated in STREAM Stage 2. Lancet Global Health 2023; 11 (2), e265-e277

Malaisamy Muniyandi, N Karikalan, Banurekha V, Kavitha Rajsekar, C Padmapriyadarsini. Cost Effectiveness of a Shorter Moxifloxacin Based Regimen for Treating Drug Sensitive Tuberculosis in India. Trop Med Infect Dis 2022; 7: 288.

Malaisamy Muniyandi, Pravin Kumar Singh, Yamini A, N Karikalan, C Padmapriyadarsini. A national-level analysis of life expectancy associated with the COVID-19 pandemic in India. Front Public Health 2022; 10:1000933.

Malaisamy Muniyandi, J Lavanya, N Karikalan, B Saravanana, S Senthil, S Sriram, Rajesh Mondal. Estimating TB diagnostic costs incurred under the National Tuberculosis Elimination Programme: a costing study from Tamil Nadu, South India. International Health 2021; 13(6), 536–544.

Conducting Health Technology Assessment (HTA) studies to support policy decisions of the Department of Health Research (DHR), Government of India.

Providing Technical Support to DHR for HTA for developing a policy perspective for HTA for use in public health programs in the country

Undertake HTA in terms of medical effectiveness, cost effectiveness, appropriateness, efficacy, safety, psychological, social, ethical, organizational and economic aspects

To promote introduction and assessment of new and existing health technologies in the system and will provide support for adoption of health technologies

To build capacity in the country towards Health Technology Assessment